Affordable Access

O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.

Authors
Type
Published Article
Journal
Cancer chemotherapy and pharmacology
Publication Date
Volume
60
Issue
3
Pages
415–421
Identifiers
PMID: 17354015
Source
Medline
License
Unknown

Abstract

Chemotherapy utilizing the MGMT inhibitor O6-benzylguanine and BCNU results in inhibition of MGMT activity in malignant plasma cells and produces meaningful responses in a modest proportion of patients with multiple myeloma. Hematologic toxicity with this regimen is significant and dose-limiting.

Statistics

Seen <100 times